Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14943686 | 0.84 | SMN1; SMN2 (0.37) | MMP13MEN1KMT2A | |
| SCHEMBL15219743 | 0.84 | SMN1; SMN2 (0.37) | MMP13MEN1KMT2A | |
| SCHEMBL14943358 | 0.84 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL15219816 | 0.78 | — | — | |
| SCHEMBL26462890 | 0.78 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL24741522 | 0.76 | CYP3A4 (0.42) | MEN1KMT2A | |
| SCHEMBL14241689 | 0.76 | CYP3A4 (0.42) | MEN1KMT2A | |
| SCHEMBL7765975 | 0.76 | CTSC (0.32) | MMP13 | |
| SCHEMBL14729745 | 0.76 | CYP3A4 (0.42) | MEN1KMT2A | |
| SCHEMBL8241440 | 0.74 | ALDH1A1 (0.40) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | MMP13 381/4885MEN1 3395/4885KMT2A 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.